Superannuation is an important part of building long-term wealth, but the money is generally locked away until retirement.

That is why I also like the idea of building a separate ASX share portfolio that can grow alongside it.

Here is how I would approach it.

I would make regular investing part of the plan

I would start by deciding how much money I could comfortably invest on a regular basis.

It might be $500 a month, $1,000 a month, or simply whatever is left after other financial commitments.

The important thing for me would be consistency. I would rather steadily build positions in good businesses than spend months waiting for the perfect time to enter the market.

Share prices will inevitably fluctuate, but regular investing means I can keep adding during both strong and weak periods.

I would focus on businesses that can keep growing

For a portfolio designed to build wealth outside superannuation, I would want companies with opportunities that extend well beyond the next year or two.

Xero Ltd (ASX: XRO) is the type of business I have in mind. It already serves millions of small businesses, but its potential global market is far larger. Xero can keep adding customers while expanding the financial tools available through its platform.

I would also consider businesses such as ResMed Inc. (ASX: RMD), where long-term demand could benefit from more people being diagnosed and treated for sleep apnoea.

I would not expect every investment to rocket higher. I would simply want a collection of quality businesses capable of increasing earnings and becoming more valuable over many years.

I would keep the portfolio diversified

Owning ASX shares outside superannuation also gives me the freedom to build the portfolio around my own preferences.

I could combine growth companies with more established businesses, such as big four bank National Australia Bank Ltd (ASX: NAB) or supermarket operator Coles Group Ltd (ASX: COL).

An exchange-traded fund (ETF) could make diversification even easier. The Vanguard MSCI Index International Shares ETF (ASX: VGS), for example, would give me exposure to a large collection of global companies alongside my Australian holdings.

I think that mix would make me less dependent on any one company, sector, or even the Australian economy.

I would give the portfolio a purpose

One reason I like building wealth outside superannuation is flexibility.

The portfolio could eventually help fund an earlier retirement, reduce working hours, pay for travel, or simply provide another financial asset that is accessible before preservation age.

During the building stage, I would generally reinvest dividends and leave successful investments alone.

But knowing the money is accessible gives the portfolio a different role from superannuation.

Foolish takeaway

I see an ASX share portfolio outside superannuation as something I could build quietly over many years.

Regular investing, quality businesses, and sensible diversification would form the foundation.

Over time, the goal would be to create another meaningful pool of wealth that gives me more choices well before traditional retirement arrives.

The post How I’d use ASX shares to build wealth outside my superannuation appeared first on The Motley Fool Australia.

More reading

• 11 ASX 200 shares with reaffirmed buy ratings post-results
• Top 3 ASX 200 shares that lifted their dividend this reporting season
• Xero shares jump 33% from a 7-year low: Buy, sell or hold?
• Own BHP, Woodside or Coles shares? Here’s what investors should know
• Are these ASX tech stocks finally a buy again?

Motley Fool contributor Grace Alvino has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed and Xero. The Motley Fool Australia has positions in and has recommended ResMed and Xero. The Motley Fool Australia has recommended Vanguard Msci Index International Shares ETF. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Telix Pharmaceuticals Ltd (ASX: TLX) shares jumped another 5% to $16.44 in Thursday afternoon trading, taking the ASX healthcare stock close to double its value since early February.

After such a stunning run, the obvious question is: where do brokers see Telix shares going over the next 12 months?

A powerful moat

Telix operates in one of the most specialised corners of healthcare: radiopharmaceuticals. These products combine radioactive isotopes with targeted therapies and diagnostics, helping doctors detect and treat diseases such as cancer with greater precision.

Importantly, this isn’t an industry where newcomers can simply walk in and compete overnight. Telix has built specialised capabilities, commercial infrastructure and a growing portfolio of products.

Turning a corner

Telix shares really turned a corner in February following a series of positive announcements from the company.

In August, Telix reported a 22% year-on-year increase in revenue to US$477 million, tracking towards the upper end of its FY26 guidance. Gross margin improved to 55%, while its Precision Medicine segment delivered an impressive 65% margin.

Adjusted EBITDA jumped 146% to US$52 million, while profit after tax reached US$38 million. That included a US$40 million payment from Regeneron.

Telix also reaffirmed its FY26 revenue and other income guidance of more than US$1 billion, with research and development expenditure expected to be between US$230 million and US$270 million.

That’s a powerful combination for Telix shares: revenue growth, expanding margins and improving profitability.

Can Telix shares keep climbing?

According to TradingView data, the analyst community remains remarkably bullish.

Fourteen of 17 analysts rate Telix shares a buy or strong buy, while the remaining three have a hold rating. The average price target sits at $25.05, implying potential upside of roughly 53% from $16.44 at the time of writing.

But there is a dissenting voice worth considering.

Bell Potter was pleased with Telix’s first-half performance but warned that competition could weigh on revenue later in the year. The broker now believes Telix shares are approaching fair value.

As a result, Bell Potter downgraded the stock from buy to hold while retaining its $19 price target.

That target still represents potential upside of roughly 16% from $16.44. However, the downgrade raises an important question after Telix’s extraordinary gains: how much of the good news is already priced in?

Foolish takeaway?

For investors, the bull case remains compelling. Telix is growing rapidly in a specialised market, profitability is improving, and most brokers still see substantial upside. But after a 98% surge, expectations are inevitably higher.

Telix shares may have plenty more room to run, but investors are no longer buying an undiscovered biotech. They’re buying a rapidly growing healthcare company with a much higher valuation and much higher expectations.

The post Telix shares are up 98%: Is there more upside to come? appeared first on The Motley Fool Australia.

More reading

• Telix shares are tumbling. Is the stock finally at fair value?
• Why were Telix shares just downgraded?
• 5 things to watch on the ASX 200 on Friday
• 7 ASX 200 shares with reaffirmed buy ratings this week
• Telix Pharmaceuticals delivers robust half-year earnings and pipeline progress

Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

S&P/ASX 200 Index (ASX: XJO) shares are up 0.55% at 9,027.8 points on Thursday.

Following the August reporting season, brokers have reviewed their ratings and 12-month price targets on hundreds of ASX stocks.

Here are some companies that scored reaffirmed buy ratings following their latest financial reports.

CSL Ltd (ASX: CSL)

The CSL share price is $175.12, up 0.7% today.

Over the past month, this ASX 200 healthcare share has ripped 41% higher.

Morgans renewed its buy rating on CSL shares with a 12-month price target of $187.71.

This suggests a potential 7% upside ahead.

Mineral Resources Ltd (ASX: MIN)

The Mineral Resources share price is $63.69, up 2.5% today.

This ASX 200 mining share has ascended 10% over the past month.

RBC Capital reiterated its buy rating on Mineral Resources shares with a price target of $80.

This implies a potential 25% upside ahead.

Santos Ltd (ASX: STO)

The Santos share price is $8.26, up 7.4% today.

This ASX 200 energy share has increased 8% over the past month.

Citi renewed its buy rating on Santos shares.

The broker raised its 12-month price target from $8.30 to $9.

This suggests a potential 9% upside ahead.

BHP Group Ltd (ASX: BHP)

The BHP share price is $64.01, down 1% today after going ex-dividend.

Over the past month, this ASX 200 copper share has risen 5%.

Morgan Stanley reaffirmed its buy rating on BHP shares.

The broker raised its 12-month target from $67.50 to $68.

This suggests a potential 6% upside ahead.

Lynas Rare Earths Ltd (ASX: LYC)

The Lynas share price is $15.46, up 2.3% today.

This ASX 200 mining share has leapt 10% over the past month.

JP Morgan reiterated its buy rating on Lynas shares with a price target of $19.10.

This implies a potential 23% upside ahead.

Nine Entertainment Co. Holdings Ltd (ASX: NEC)

The Nine Entertainment share price is 97 cents, up 1% today.

Over the past month, this ASX 200 communications share has fallen 2%.

Morgan Stanley reaffirmed its buy rating on Nine shares with a 12-month target of $1.40.

This suggests a potential 42% upside ahead.

Coles Group Ltd (ASX: COL)

The Coles share price is $23.58, up 0.3% today.

Over the past month, this ASX 200 consumer staples share has fallen 3%.

Morgan Stanley reiterated its buy rating on Coles shares.

The broker increased its price target from $25 to $25.80.

This implies potential capital gains of 9% ahead.

Qantas Airways Ltd (ASX: QAN)

The Qantas share price is $9.35, up 1.3% today.

This ASX 200 travel share has fallen 9% over the past month.

Morgan Stanley renewed its buy rating on Qantas shares with a $12.80 target.

This implies potential capital growth of 36% over the next year.

NextDC Ltd (ASX: NXT)

The NextDC share price is $12.70, down 0.2% today.

Over the past month, this ASX 200 tech share has fallen 6%.

UBS renewed its buy rating on NextDC shares with a $23.45 target.

This suggests a potential 85% upside ahead.

Paladin Energy Ltd (ASX: PDN)

The Paladin Energy share price is $11.31, up 1.8% today.

Over the past month, this ASX 200 uranium share has soared 20%.

Canaccord Genuity renewed its buy rating on Paladin Energy shares.

The broker raised its 12-month price target from $15.40 to $15.80.

This suggests a potential 40% upside ahead.

Flight Centre Travel Group Ltd (ASX: FLT)

The Flight Centre share price is $11.52, down 0.3% today.

Over the past month, this ASX 200 travel share has fallen 13%.

JP Morgan renewed its buy rating on Flight Centre shares with a $15.30 target.

This suggests a potential 32% upside ahead.

The post 11 ASX 200 shares with reaffirmed buy ratings post-results appeared first on The Motley Fool Australia.

More reading

• How CSL shares skyrocketed 39% in August
• Top 3 ASX 200 shares that lifted their dividend this reporting season
• Own BHP, Woodside or Coles shares? Here’s what investors should know
• Buying Santos shares? Here’s why the company is celebrating this production milestone
• How to invest in quantum computing on the ASX

Citigroup is an advertising partner of Motley Fool Money. JPMorgan Chase is an advertising partner of Motley Fool Money. Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL and JPMorgan Chase. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Lynas Rare Earths Ltd. The Motley Fool Australia has recommended BHP Group, CSL, Flight Centre Travel Group, and Nine Entertainment. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.